Awakn CEO Anthony Tennyson: Developing and Delivering the Next Generation of Addiction Treatments


DISCLAIMER: GOLDINVESTMENTCOMPANIES.COM IS AN AFFILIATED PARTNER FOR GOLDCO PRECIOUS METALS, AUGUSTA PRECIOUS METALS, AND BIRCH GOLD GROUP, PROMOTING THEIR GOLD IRA, GOLD 401K TRANSFER AND BITCOIN IRA SERVICES AND PRODUCTS.

Awakn Life Sciences CEO Anthony Tennyson believes the company is at the cutting edge of taking a revolutionary approach to #addiction and #mentalhealth #treatment.

Awakn Life Sciences (NEO:AWAKN, OTCQB:AWKNF) is currently developing compounds and therapies delivered by trained therapists at their wholly-owned clinical environments to treat both substance and behavior addiction.

00:24 Awakn Life Sciences: psychedelics to treat addiction in the UK and Europe
00:57 Biotechnology company focused on developing and delivering medicines to better treat addiction
03:05 Treatments targeting substance addictions
03:22 Company growth strategy
03:47 A significant pipeline of medicines and therapies
04:33 How Awakn’s medicines and therapies work
05:08 Ketamine: a Schedule 2 compound in the UK
06:27 The psychedelics assisted psychotherapy approach
08:07 Clinics in London, Bristol and Manchester
08:41 Expansion plans across the UK and the EU
10:35 Active workstreams in development or research program
11:28 Current clinical trials
13:12 Awakn Life Sciences’ core purpose

“That is exactly what we’re doing in London and what we’ll be doing in Bristol and Manchester as we open up our first three of 20 clinics in the UK this year. We’ll treat people with proprietary therapy, proprietary compounds, and well trained staff in a specifically designed clinical environment,” Tennyson said.

The company recently announced a 10-year lease to open Awakn Clinics London while initiating the first-ever study investigating ketamine in gambling addiction.

Tennyson also added that they’re taking a radical approach to develop a psychedelics package to better treat addiction.

“Psychedelic assisted psychotherapy is different, it is revolutionary. You’ll need the compound, the therapy, the therapist, and the clinical environment, all of which are specifically designed to improve the probability of success to come up with the next generation of better treatments.”

________________________________________________________________

Investing News Network (INN)

Find out more about investing by INN @
https://investingnews.com/

Want a FREE investor kit? Download here↓
https://bit.ly/31NNNTR

Follow us Facebook:
https://www.facebook.com/investing.news.your.trusted.source

________________________________________________________________

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

You May Also Like

>